AstraZeneca has become the only current UK-listed company to reach a £200bn valuation, in a vindication of the company’s bet on developing a leading portfolio of cancer drugs.
The UK drugmaker’s shares rose 1.1 per cent on Tuesday to reach a market capitalisation of £200.3bn. Its stock has risen by almost 20 per cent this year, after chief executive Pascal Soriot outlined plans in May for the company to reach $80bn in annual revenue by 2030.
您已阅读16%（566字），剩余84%（2985字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。